Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.45 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.45 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7312616 | 0.91 | ORAI1 (0.59) | ORAI1THRBRXFP1KLKB1TP53 | |
| SCHEMBL7326066 | 0.91 | ORAI1 (0.64) | ORAI1THRBRXFP1GRM5MAPT | |
| SCHEMBL7319850 | 0.89 | ORAI1 (0.64) | ORAI1THRBRXFP1KLKB1MAPT | |
| SCHEMBL7321659 | 0.83 | EPHX2 (0.54) | ORAI1THRBRXFP1GRM5MAPT | |
| SCHEMBL7327450 | 0.82 | ORAI1 (0.63) | ORAI1THRBKLKB1MAPTSMN1; SMN2 | |
| SCHEMBL7328606 | 0.82 | THRB (0.59) | ORAI1THRBKLKB1GRM5MAPT | |
| SCHEMBL7326377 | 0.79 | ORAI1 (0.74) | ORAI1THRBMAPTTP53TRPC1 | |
| SCHEMBL7318446 | 0.79 | ORAI1 (0.74) | ORAI1THRBMAPTTP53TRPC1 | |
| SCHEMBL18604889 | 0.79 | KLKB1 (0.64) | KLKB1 | |
| SCHEMBL31067428 | 0.79 | KLKB1 (0.64) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES | 2001-11-22 | — | — | US | claimed |
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | IL5, IL2, IL4 | ORAI1 3522/4885THRB 3730/4885RXFP1 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.